1 October 2026

Notification no. 77/2026

Transactions made by persons obliged to report transactions to the Danish FSA and Nasdaq Copenhagen, cf. the EU Market Abuse Regulation.

In connection with the share buy-back program in Danske Bank A/S, APMH Invest A/S continuously sells shares pro rata.

For further details, please find the attached templates for notifications and public disclosure of transactions by persons discharging managerial responsibilities and persons closely associated with them.

Contact: Stefan Kailay Wind, Nordic Head of Media Relations, tel. +45 45 14 14 00

Attachment

FORM 8.3

PUBLIC OPENING POSITION DISCLOSURE/DEALING DISCLOSURE BY
A PERSON WITH INTERESTS IN RELEVANT SECURITIES REPRESENTING 1% OR MORE
Rule 8.3 of the Takeover Code (the “Code”)

1.        KEY INFORMATION

(a)   Full name of discloser: Man Group PLC
(b)   Owner or controller of interests and short positions disclosed, if different from 1(a):
        The naming of nominee or vehicle companies is insufficient. For a trust, the trustee(s), settlor and beneficiaries must be named.
 
(c)   Name of offeror/offeree in relation to whose relevant securities this form relates:
        Use a separate form for each offeror/offeree
Gamma Communications plc
(d)   If an exempt fund manager connected with an offeror/offeree, state this and specify identity of offeror/offeree:  
(e)   Date position held/dealing undertaken:
        For an opening position disclosure, state the latest practicable date prior to the disclosure
30/09/2026
(f)   In addition to the company in 1(c) above, is the discloser making disclosures in respect of any other party to the offer? NO

2.        POSITIONS OF THE PERSON MAKING THE DISCLOSURE

If there are positions or rights to subscribe to disclose in more than one class of relevant securities of the offeror or offeree named in 1(c), copy table 2(a) or (b) (as appropriate) for each additional class of relevant security.

(a)      Interests and short positions in the relevant securities of the offeror or offeree to which the disclosure relates following the dealing (if any)

Class of relevant security: 0.25p ordinary
  Interests Short positions
Number % Number %
(1)   Relevant securities owned and/or controlled:        
(2)   Cash-settled derivatives: 927,208 1.04    
(3)   Stock-settled derivatives (including options) and agreements to purchase/sell:        
        TOTAL: 927,208 1.04    

All interests and all short positions should be disclosed.

Details of any open stock-settled derivative positions (including traded options), or agreements to purchase or sell relevant securities, should be given on a Supplemental Form 8 (Open Positions).

(b)      Rights to subscribe for new securities (including directors’ and other employee options)

Class of relevant security in relation to which subscription right exists:  
Details, including nature of the rights concerned and relevant percentages:  

3.        DEALINGS (IF ANY) BY THE PERSON MAKING THE DISCLOSURE

Where there have been dealings in more than one class of relevant securities of the offeror or offeree named in 1(c), copy table 3(a), (b), (c) or (d) (as appropriate) for each additional class of relevant security dealt in.

The currency of all prices and other monetary amounts should be stated.

(a)        Purchases and sales

Class of relevant security Purchase/sale Number of securities Price per unit

(b)        Cash-settled derivative transactions

Class of relevant security Product description
e.g. CFD
Nature of dealing
e.g. opening/closing a long/short position, increasing/reducing a long/short position
Number of reference securities Price per unit
0.25p ordinary Equity swap Reducing a long position 867 11.2528 GBP
0.25p ordinary Equity swap Reducing a long position 1,191 11.2500 GBP
0.25p ordinary Equity swap Reducing a long position 731 11.2437 GBP
0.25p ordinary Equity swap Increasing a long position 3,155 11.2520 GBP
0.25p ordinary Equity swap Increasing a long position 114 11.1917 GBP
0.25p ordinary Equity swap Reducing a long position 3,155 11.2576 GBP
0.25p ordinary Equity swap Increasing a long position 3,155 11.2576 GBP
0.25p ordinary Equity swap Increasing a long position 36,243 11.2520 GBP
0.25p ordinary Equity swap Increasing a long position 1,274 11.1917 GBP
0.25p ordinary Equity swap Reducing a long position 36,243 11.2576 GBP
0.25p ordinary Equity swap Increasing a long position 36,243 11.2576 GBP
0.25p ordinary Equity swap Increasing a long position 1,877 11.2520 GBP
0.25p ordinary Equity swap Increasing a long position 68 11.1917 GBP
0.25p ordinary Equity swap Reducing a long position 1,877 11.2576 GBP
0.25p ordinary Equity swap Increasing a long position 1,877 11.2576 GBP
0.25p ordinary Equity swap Increasing a long position 443 11.2520 GBP
0.25p ordinary Equity swap Increasing a long position 16 11.1917 GBP
0.25p ordinary Equity swap Reducing a long position 443 11.2576 GBP
0.25p ordinary Equity swap Increasing a long position 443 11.2576 GBP
0.25p ordinary Equity swap Increasing a long position 24,019 11.2520 GBP
0.25p ordinary Equity swap Increasing a long position 884 11.1917 GBP
0.25p ordinary Equity swap Reducing a long position 24,019 11.2576 GBP
0.25p ordinary Equity swap Increasing a long position 24,019 11.2576 GBP
0.25p ordinary Equity swap Increasing a long position 495 11.2520 GBP
0.25p ordinary Equity swap Increasing a long position 18 11.1917 GBP
0.25p ordinary Equity swap Reducing a long position 495 11.2576 GBP
0.25p ordinary Equity swap Increasing a long position 495 11.2576 GBP
0.25p ordinary Equity swap Increasing a long position 8,218 11.2520 GBP
0.25p ordinary Equity swap Increasing a long position 272 11.1917 GBP
0.25p ordinary Equity swap Reducing a long position 8,218 11.2576 GBP
0.25p ordinary Equity swap Increasing a long position 8,218 11.2576 GBP

        
(c)        Stock-settled derivative transactions (including options)

(i)        Writing, selling, purchasing or varying

Class of relevant security Product description e.g. call option Writing, purchasing, selling, varying etc. Number of securities to which option relates Exercise price per unit Type
e.g. American, European etc.
Expiry date Option money paid/ received per unit

(ii)        Exercise

Class of relevant security Product description
e.g. call option
Exercising/ exercised against Number of securities Exercise price per unit

(d)        Other dealings (including subscribing for new securities)

Class of relevant security Nature of dealing
e.g. subscription, conversion
Details Price per unit (if applicable)

4.        OTHER INFORMATION

(a)        Indemnity and other dealing arrangements

Details of any indemnity or option arrangement, or any agreement or understanding, formal or informal, relating to relevant securities which may be an inducement to deal or refrain from dealing entered into by the person making the disclosure and any party to the offer or any person acting in concert with a party to the offer:
None

(b)        Agreements, arrangements or understandings relating to options or derivatives

Details of any agreement, arrangement or understanding, formal or informal, between the person making the disclosure and any other person relating to:
(i)   the voting rights of any relevant securities under any option; or
(ii)   the voting rights or future acquisition or disposal of any relevant securities to which any derivative is referenced:
None

(c)        Attachments

Is a Supplemental Form 8 (Open Positions) attached? NO

Date of disclosure: 01/10/2026
Contact name: Molly Childs
Telephone number: +44 20 7144 3714

Public disclosures under Rule 8 of the Code must be made to a Regulatory Information Service.

The Panel’s Market Surveillance Unit is available for consultation in relation to the Code’s disclosure requirements on +44 (0)20 7638 0129.

The Code can be viewed on the Panel’s website at www.thetakeoverpanel.org.uk.

FORM 8.3

PUBLIC OPENING POSITION DISCLOSURE/DEALING DISCLOSURE BY
A PERSON WITH INTERESTS IN RELEVANT SECURITIES REPRESENTING 1% OR MORE
Rule 8.3 of the Takeover Code (the “Code”)

1.        KEY INFORMATION

(a)   Full name of discloser: Man Group PLC
(b)   Owner or controller of interests and short positions disclosed, if different from 1(a):
        The naming of nominee or vehicle companies is insufficient. For a trust, the trustee(s), settlor and beneficiaries must be named.
 
(c)   Name of offeror/offeree in relation to whose relevant securities this form relates:
        Use a separate form for each offeror/offeree
RHI Magnesita N.V.
(d)   If an exempt fund manager connected with an offeror/offeree, state this and specify identity of offeror/offeree:  
(e)   Date position held/dealing undertaken:
        For an opening position disclosure, state the latest practicable date prior to the disclosure
30/09/2026
(f)   In addition to the company in 1(c) above, is the discloser making disclosures in respect of any other party to the offer? YES
Offeree: Vesuvius plc

2.        POSITIONS OF THE PERSON MAKING THE DISCLOSURE

If there are positions or rights to subscribe to disclose in more than one class of relevant securities of the offeror or offeree named in 1(c), copy table 2(a) or (b) (as appropriate) for each additional class of relevant security.

(a)      Interests and short positions in the relevant securities of the offeror or offeree to which the disclosure relates following the dealing (if any)

Class of relevant security: €1 ordinary
  Interests Short positions
Number % Number %
(1)   Relevant securities owned and/or controlled: 1,144,813 2.41    
(2)   Cash-settled derivatives: 343,082 0.72    
(3)   Stock-settled derivatives (including options) and agreements to purchase/sell:        
        TOTAL: 1,487,895 3.14    

All interests and all short positions should be disclosed.

Details of any open stock-settled derivative positions (including traded options), or agreements to purchase or sell relevant securities, should be given on a Supplemental Form 8 (Open Positions).

(b)      Rights to subscribe for new securities (including directors’ and other employee options)

Class of relevant security in relation to which subscription right exists:  
Details, including nature of the rights concerned and relevant percentages:  

3.        DEALINGS (IF ANY) BY THE PERSON MAKING THE DISCLOSURE

Where there have been dealings in more than one class of relevant securities of the offeror or offeree named in 1(c), copy table 3(a), (b), (c) or (d) (as appropriate) for each additional class of relevant security dealt in.

The currency of all prices and other monetary amounts should be stated.

(a)        Purchases and sales

Class of relevant security Purchase/sale Number of securities Price per unit

(b)        Cash-settled derivative transactions

Class of relevant security Product description
e.g. CFD
Nature of dealing
e.g. opening/closing a long/short position, increasing/reducing a long/short position
Number of reference securities Price per unit
€1 ordinary Equity swap Reducing a long position 9,361 28.9648 EUR
€1 ordinary Equity swap Reducing a long position 11,702 29.9317 EUR

        
(c)        Stock-settled derivative transactions (including options)

(i)        Writing, selling, purchasing or varying

Class of relevant security Product description e.g. call option Writing, purchasing, selling, varying etc. Number of securities to which option relates Exercise price per unit Type
e.g. American, European etc.
Expiry date Option money paid/ received per unit

(ii)        Exercise

Class of relevant security Product description
e.g. call option
Exercising/ exercised against Number of securities Exercise price per unit

(d)        Other dealings (including subscribing for new securities)

Class of relevant security Nature of dealing
e.g. subscription, conversion
Details Price per unit (if applicable)

4.        OTHER INFORMATION

(a)        Indemnity and other dealing arrangements

Details of any indemnity or option arrangement, or any agreement or understanding, formal or informal, relating to relevant securities which may be an inducement to deal or refrain from dealing entered into by the person making the disclosure and any party to the offer or any person acting in concert with a party to the offer:
None

(b)        Agreements, arrangements or understandings relating to options or derivatives

Details of any agreement, arrangement or understanding, formal or informal, between the person making the disclosure and any other person relating to:
(i)   the voting rights of any relevant securities under any option; or
(ii)   the voting rights or future acquisition or disposal of any relevant securities to which any derivative is referenced:
None

(c)        Attachments

Is a Supplemental Form 8 (Open Positions) attached? NO

Date of disclosure: 01/10/2026
Contact name: Molly Childs
Telephone number: +44 20 7144 3714

Public disclosures under Rule 8 of the Code must be made to a Regulatory Information Service.

The Panel’s Market Surveillance Unit is available for consultation in relation to the Code’s disclosure requirements on +44 (0)20 7638 0129.

The Code can be viewed on the Panel’s website at www.thetakeoverpanel.org.uk.

Collaboration to identify optimal combination therapies, predictive biomarkers and patient populations for Rakovina’s ATR inhibitor program

VANCOUVER, British Columbia, Oct. 01, 2026 (GLOBE NEWSWIRE) — Rakovina Therapeutics Inc. (TSX-V: RKV) (FSE: 7JO0) (OTCMKTS: RKVTF) a biopharmaceutical company advancing innovative cancer therapies through AI-powered drug discovery, today announced a research collaboration with Boston-based Celvion Therapeutics (“Celvion”) to leverage Celvion’s proprietary EMphora™ artificial intelligence platform to identify novel precision medicine strategies designed to accelerate the development of Rakovina’s ATR inhibitor program.

The collaboration will initially focus on indications where EMphora™ will analyze large-scale clinical outcomes and real-world patient data to identify therapeutic targets that may enhance the activity of Rakovina’s ATR inhibitor. In addition to evaluating potential drug combinations, the analysis will search for previously unrecognized therapeutic opportunities, predictive biomarkers, and patient subgroups most likely to benefit from ATR-targeted therapies.

Unlike conventional preclinical discovery approaches, the collaboration will utilize artificial intelligence to interrogate real-world clinical evidence, helping identify the most promising drug combinations and patient populations before advancing into further development. By combining Rakovina’s expertise in synthetic lethality and DNA damage response therapeutics with Celvion’s AI-powered clinical discovery platform, the companies aim to improve development efficiency, reduce clinical risk, and accelerate the delivery of precision medicines to patients with difficult-to-treat cancers.

The companies expect the analysis to generate clinically actionable hypotheses that will help prioritize future combination studies, guide biomarker-driven patient selection strategies, and inform the design of subsequent clinical development programs.

“We have learned how to use multiple specialized AI platforms to accelerate the drug discovery and development process rather than relying on a single platform. Our team selects the right tool for each challenge, from generative design to large-scale screening, to develop molecules that exploit vulnerabilities in how cancer cells repair DNA damage,” said Kim Oishi, Chief Executive Officer of Rakovina Therapeutics. “Working with Celvion extends that approach into clinical strategy, using advanced AI to identify the patient populations and drug combinations where our ATR inhibitor program can have the greatest impact.”

“EMphora was built to uncover meaningful therapeutic insights directly from clinical outcomes and existing patient data,” said Mi Yang, Chief Executive Officer of Celvion Therapeutics. “By collaborating with Rakovina, we have an opportunity to identify combination therapies and biomarkers that may not be apparent through conventional research methods. Our objective is to generate actionable evidence that helps guide smarter clinical development and ultimately benefits patients.”

“Synthetic lethality offers tremendous promise in oncology, but its greatest impact will come from identifying the right combinations for the right patients,” said Dr. Mads Daugaard, President and Chief Scientific Officer of Rakovina Therapeutics. “This collaboration gives us the opportunity to rigorously evaluate ATR-based combination strategies while exploring additional biomarkers and therapeutic targets that could further enhance clinical benefit. These insights will help shape the next generation of our development strategy.”

Rakovina and Celvion intend to commit appropriate scientific, technical and other resources to support the collaboration and advance the resulting opportunities. As the work progresses and promising development opportunities are identified, the companies expect to explore appropriate co-development and economic arrangements to support subsequent stages of development.

The collaboration reflects Rakovina’s broader strategy of integrating cutting-edge computational biology, translational science, and precision oncology to build a smarter, faster, and more targeted approach to cancer drug development. By leveraging artificial intelligence alongside world-class science, Rakovina continues to position itself at the forefront of precision oncology innovation with the goal of delivering transformative therapies for patients facing significant unmet medical needs.

About Rakovina Therapeutics Inc.

Rakovina Therapeutics is a biopharmaceutical research company focused on the development of innovative cancer treatments. Our work is based on unique technologies for targeting the DNA-damage response powered by Artificial Intelligence (AI) using validated, proprietary platforms. By using AI, we can review and optimize drug candidates at a much greater pace than ever before.

The Company has established a pipeline of distinctive DNA-damage response inhibitors with the goal of advancing one or more drug candidates into human clinical trials in collaboration with pharmaceutical partners. Further information may be found at www.rakovinatherapeutics.com.

Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in policies of the TSXV) accepts responsibility for the adequacy or accuracy of this release.

For Further Information Contact:

Kim Oishi
CEO
Kim.oishi@rakovinatherapeutics.com

Mark Mitchell
IR@rakovinatherapeutics.com

Notice Regarding Rakovina Therapeutics Forward-Looking Statements:

This release includes forward-looking statements regarding the company and its respective business, which may include, but is not limited to, statements with respect to the proposed business plan of the company and other statements. Often, but not always, forward-looking statements can be identified by the use of words such as “plans,” “is expected,” “expects,” “scheduled,” “intends,” “contemplates,” “anticipates,” “believes,” “proposes” or variations (including negative variations) of such words and phrases, or state that certain actions, events, or results “may,” “could,” “would,” “might,” or “will” be taken, occur, or be achieved. Such statements are based on the current expectations of the management of the company. The forward-looking events and circumstances discussed in this release may not occur by certain specified dates or at all and could differ materially as a result of known and unknown risk factors and uncertainties affecting the company, including risks regarding the biopharmaceutical industry, economic factors, regulatory factors, the equity markets generally, and risks associated with growth and competition.

Although the company has attempted to identify important factors that could cause actual actions, events, or results to differ materially from those described in forward-looking statements, there may be other factors that cause actions, events, or results to differ from those anticipated, estimated, or intended. No forward-looking statement can be guaranteed. Except as required by applicable securities laws, forward-looking statements speak only as of the date on which they are made, and the company undertakes no obligation to publicly update or revise any forward-looking statement, whether as a result of new information, future events, or otherwise. The reader is referred to the company’s most recent filings on SEDAR+ for a more complete discussion of all applicable risk factors and their potential effects, copies of which may be accessed through the company’s profile page at www.sedar.com.

#FORM 8.3

PUBLIC OPENING POSITION DISCLOSURE/DEALING DISCLOSURE BY
A PERSON WITH INTERESTS IN RELEVANT SECURITIES REPRESENTING 1% OR MORE
Rule 8.3 of the Takeover Code (the “Code”)

1.        KEY INFORMATION

(a)   Full name of discloser: Man Group PLC
(b)   Owner or controller of interests and short positions disclosed, if different from 1(a):
        The naming of nominee or vehicle companies is insufficient. For a trust, the trustee(s), settlor and beneficiaries must be named.
 
(c)   Name of offeror/offeree in relation to whose relevant securities this form relates:
        Use a separate form for each offeror/offeree
Rotork Plc
(d)   If an exempt fund manager connected with an offeror/offeree, state this and specify identity of offeror/offeree:  
(e)   Date position held/dealing undertaken:
        For an opening position disclosure, state the latest practicable date prior to the disclosure
30/09/2026
(f)   In addition to the company in 1(c) above, is the discloser making disclosures in respect of any other party to the offer? NO

2.        POSITIONS OF THE PERSON MAKING THE DISCLOSURE

If there are positions or rights to subscribe to disclose in more than one class of relevant securities of the offeror or offeree named in 1(c), copy table 2(a) or (b) (as appropriate) for each additional class of relevant security.

(a)      Interests and short positions in the relevant securities of the offeror or offeree to which the disclosure relates following the dealing (if any)

Class of relevant security: 0.5p ordinary
  Interests Short positions
Number % Number %
(1)   Relevant securities owned and/or controlled:        
(2)   Cash-settled derivatives: 15,123,878 1.85 11,209 0.00
(3)   Stock-settled derivatives (including options) and agreements to purchase/sell:        
        TOTAL: 15,123,878 1.85 11,209 0.00

All interests and all short positions should be disclosed.

Details of any open stock-settled derivative positions (including traded options), or agreements to purchase or sell relevant securities, should be given on a Supplemental Form 8 (Open Positions).

(b)      Rights to subscribe for new securities (including directors’ and other employee options)

Class of relevant security in relation to which subscription right exists:  
Details, including nature of the rights concerned and relevant percentages:  

3.        DEALINGS (IF ANY) BY THE PERSON MAKING THE DISCLOSURE

Where there have been dealings in more than one class of relevant securities of the offeror or offeree named in 1(c), copy table 3(a), (b), (c) or (d) (as appropriate) for each additional class of relevant security dealt in.

The currency of all prices and other monetary amounts should be stated.

(a)        Purchases and sales

Class of relevant security Purchase/sale Number of securities Price per unit

(b)        Cash-settled derivative transactions

Class of relevant security Product description
e.g. CFD
Nature of dealing
e.g. opening/closing a long/short position, increasing/reducing a long/short position
Number of reference securities Price per unit
0.5p ordinary Equity swap Reducing a long position 1,662 4.8782 GBP
0.5p ordinary Equity swap Increasing a long position 1,697 4.8794 GBP
0.5p ordinary Equity swap Increasing a long position 22,354 4.8794 GBP
0.5p ordinary Equity swap Increasing a long position 482 4.8794 GBP

(c)        Stock-settled derivative transactions (including options)

(i)        Writing, selling, purchasing or varying

Class of relevant security Product description e.g. call option Writing, purchasing, selling, varying etc. Number of securities to which option relates Exercise price per unit Type
e.g. American, European etc.
Expiry date Option money paid/ received per unit

(ii)        Exercise

Class of relevant security Product description
e.g. call option
Exercising/ exercised against Number of securities Exercise price per unit

(d)        Other dealings (including subscribing for new securities)

Class of relevant security Nature of dealing
e.g. subscription, conversion
Details Price per unit (if applicable)

4.        OTHER INFORMATION

(a)        Indemnity and other dealing arrangements

Details of any indemnity or option arrangement, or any agreement or understanding, formal or informal, relating to relevant securities which may be an inducement to deal or refrain from dealing entered into by the person making the disclosure and any party to the offer or any person acting in concert with a party to the offer:
None

(b)        Agreements, arrangements or understandings relating to options or derivatives

Details of any agreement, arrangement or understanding, formal or informal, between the person making the disclosure and any other person relating to:
(i)   the voting rights of any relevant securities under any option; or
(ii)   the voting rights or future acquisition or disposal of any relevant securities to which any derivative is referenced:
None

(c)        Attachments

Is a Supplemental Form 8 (Open Positions) attached? NO

Date of disclosure: 01/10/2026
Contact name: Molly Childs
Telephone number: +44 20 7144 3714

Public disclosures under Rule 8 of the Code must be made to a Regulatory Information Service.

The Panel’s Market Surveillance Unit is available for consultation in relation to the Code’s disclosure requirements on +44 (0)20 7638 0129.

The Code can be viewed on the Panel’s website at www.thetakeoverpanel.org.uk.

FORM 8.3

PUBLIC OPENING POSITION DISCLOSURE/DEALING DISCLOSURE BY
A PERSON WITH INTERESTS IN RELEVANT SECURITIES REPRESENTING 1% OR MORE
Rule 8.3 of the Takeover Code (the “Code”)

1.        KEY INFORMATION

(a)   Full name of discloser: Man Group PLC
(b)   Owner or controller of interests and short positions disclosed, if different from 1(a):
        The naming of nominee or vehicle companies is insufficient. For a trust, the trustee(s), settlor and beneficiaries must be named.
 
(c)   Name of offeror/offeree in relation to whose relevant securities this form relates:
        Use a separate form for each offeror/offeree
Sthree plc
(d)   If an exempt fund manager connected with an offeror/offeree, state this and specify identity of offeror/offeree:  
(e)   Date position held/dealing undertaken:
        For an opening position disclosure, state the latest practicable date prior to the disclosure
30/09/2026
(f)   In addition to the company in 1(c) above, is the discloser making disclosures in respect of any other party to the offer? NO

2.        POSITIONS OF THE PERSON MAKING THE DISCLOSURE

If there are positions or rights to subscribe to disclose in more than one class of relevant securities of the offeror or offeree named in 1(c), copy table 2(a) or (b) (as appropriate) for each additional class of relevant security.

(a)      Interests and short positions in the relevant securities of the offeror or offeree to which the disclosure relates following the dealing (if any)

Class of relevant security: 1p ordinary
  Interests Short positions
Number % Number %
(1)   Relevant securities owned and/or controlled: 6,699,267 5.50    
(2)   Cash-settled derivatives: 3,927,942 3.22 11,597 0.00
(3)   Stock-settled derivatives (including options) and agreements to purchase/sell:        
        TOTAL: 10,627,209 8.72 11,597 0.00

All interests and all short positions should be disclosed.

Details of any open stock-settled derivative positions (including traded options), or agreements to purchase or sell relevant securities, should be given on a Supplemental Form 8 (Open Positions).

(b)      Rights to subscribe for new securities (including directors’ and other employee options)

Class of relevant security in relation to which subscription right exists:  
Details, including nature of the rights concerned and relevant percentages:  

3.        DEALINGS (IF ANY) BY THE PERSON MAKING THE DISCLOSURE

Where there have been dealings in more than one class of relevant securities of the offeror or offeree named in 1(c), copy table 3(a), (b), (c) or (d) (as appropriate) for each additional class of relevant security dealt in.

The currency of all prices and other monetary amounts should be stated.

(a)        Purchases and sales

Class of relevant security Purchase/sale Number of securities Price per unit

(b)        Cash-settled derivative transactions

Class of relevant security Product description
e.g. CFD
Nature of dealing
e.g. opening/closing a long/short position, increasing/reducing a long/short position
Number of reference securities Price per unit
1p ordinary Equity swap Increasing a short position 600 3.0000 GBP
1p ordinary Equity swap Reducing a long position 129,475 3.0282 GBP

        
(c)        Stock-settled derivative transactions (including options)

(i)        Writing, selling, purchasing or varying

Class of relevant security Product description e.g. call option Writing, purchasing, selling, varying etc. Number of securities to which option relates Exercise price per unit Type
e.g. American, European etc.
Expiry date Option money paid/ received per unit

(ii)        Exercise

Class of relevant security Product description
e.g. call option
Exercising/ exercised against Number of securities Exercise price per unit

(d)        Other dealings (including subscribing for new securities)

Class of relevant security Nature of dealing
e.g. subscription, conversion
Details Price per unit (if applicable)

4.        OTHER INFORMATION

(a)        Indemnity and other dealing arrangements

Details of any indemnity or option arrangement, or any agreement or understanding, formal or informal, relating to relevant securities which may be an inducement to deal or refrain from dealing entered into by the person making the disclosure and any party to the offer or any person acting in concert with a party to the offer:
None

(b)        Agreements, arrangements or understandings relating to options or derivatives

Details of any agreement, arrangement or understanding, formal or informal, between the person making the disclosure and any other person relating to:
(i)   the voting rights of any relevant securities under any option; or
(ii)   the voting rights or future acquisition or disposal of any relevant securities to which any derivative is referenced:
None

(c)        Attachments

Is a Supplemental Form 8 (Open Positions) attached? NO

Date of disclosure: 01/10/2026
Contact name: Molly Childs
Telephone number: +44 20 7144 3714

Public disclosures under Rule 8 of the Code must be made to a Regulatory Information Service.

The Panel’s Market Surveillance Unit is available for consultation in relation to the Code’s disclosure requirements on +44 (0)20 7638 0129.

The Code can be viewed on the Panel’s website at www.thetakeoverpanel.org.uk.

FORM 8.3

PUBLIC OPENING POSITION DISCLOSURE/DEALING DISCLOSURE BY
A PERSON WITH INTERESTS IN RELEVANT SECURITIES REPRESENTING 1% OR MORE
Rule 8.3 of the Takeover Code (the “Code”)

1.        KEY INFORMATION

(a)   Full name of discloser: Man Group PLC
(b)   Owner or controller of interests and short positions disclosed, if different from 1(a):
        The naming of nominee or vehicle companies is insufficient. For a trust, the trustee(s), settlor and beneficiaries must be named.
 
(c)   Name of offeror/offeree in relation to whose relevant securities this form relates:
        Use a separate form for each offeror/offeree
Vesuvius plc
(d)   If an exempt fund manager connected with an offeror/offeree, state this and specify identity of offeror/offeree:  
(e)   Date position held/dealing undertaken:
        For an opening position disclosure, state the latest practicable date prior to the disclosure
30/09/2026
(f)   In addition to the company in 1(c) above, is the discloser making disclosures in respect of any other party to the offer? YES
Offeror: RHI Magnestia N.V.

2.        POSITIONS OF THE PERSON MAKING THE DISCLOSURE

If there are positions or rights to subscribe to disclose in more than one class of relevant securities of the offeror or offeree named in 1(c), copy table 2(a) or (b) (as appropriate) for each additional class of relevant security.

(a)      Interests and short positions in the relevant securities of the offeror or offeree to which the disclosure relates following the dealing (if any)

Class of relevant security: 10p ordinary
  Interests Short positions
Number % Number %
(1)   Relevant securities owned and/or controlled: 14,991,470 6.04    
(2)   Cash-settled derivatives: 999,258 0.40 468,224 0.18
(3)   Stock-settled derivatives (including options) and agreements to purchase/sell:        
        TOTAL: 15,990,728 6.44 468,224 0.18

All interests and all short positions should be disclosed.

Details of any open stock-settled derivative positions (including traded options), or agreements to purchase or sell relevant securities, should be given on a Supplemental Form 8 (Open Positions).

(b)      Rights to subscribe for new securities (including directors’ and other employee options)

Class of relevant security in relation to which subscription right exists:  
Details, including nature of the rights concerned and relevant percentages:  

3.        DEALINGS (IF ANY) BY THE PERSON MAKING THE DISCLOSURE

Where there have been dealings in more than one class of relevant securities of the offeror or offeree named in 1(c), copy table 3(a), (b), (c) or (d) (as appropriate) for each additional class of relevant security dealt in.

The currency of all prices and other monetary amounts should be stated.

(a)        Purchases and sales

Class of relevant security Purchase/sale Number of securities Price per unit
10p ordinary Sale 553 4.8000 GBP

(b)        Cash-settled derivative transactions

Class of relevant security Product description
e.g. CFD
Nature of dealing
e.g. opening/closing a long/short position, increasing/reducing a long/short position
Number of reference securities Price per unit

        
(c)        Stock-settled derivative transactions (including options)

(i)        Writing, selling, purchasing or varying

Class of relevant security Product description e.g. call option Writing, purchasing, selling, varying etc. Number of securities to which option relates Exercise price per unit Type
e.g. American, European etc.
Expiry date Option money paid/ received per unit

(ii)        Exercise

Class of relevant security Product description
e.g. call option
Exercising/ exercised against Number of securities Exercise price per unit

(d)        Other dealings (including subscribing for new securities)

Class of relevant security Nature of dealing
e.g. subscription, conversion
Details Price per unit (if applicable)

4.        OTHER INFORMATION

(a)        Indemnity and other dealing arrangements

Details of any indemnity or option arrangement, or any agreement or understanding, formal or informal, relating to relevant securities which may be an inducement to deal or refrain from dealing entered into by the person making the disclosure and any party to the offer or any person acting in concert with a party to the offer:
None

(b)        Agreements, arrangements or understandings relating to options or derivatives

Details of any agreement, arrangement or understanding, formal or informal, between the person making the disclosure and any other person relating to:
(i)   the voting rights of any relevant securities under any option; or
(ii)   the voting rights or future acquisition or disposal of any relevant securities to which any derivative is referenced:
None

(c)        Attachments

Is a Supplemental Form 8 (Open Positions) attached? NO

Date of disclosure: 01/10/2026
Contact name: Molly Childs
Telephone number: +44 20 7144 3714

Public disclosures under Rule 8 of the Code must be made to a Regulatory Information Service.

The Panel’s Market Surveillance Unit is available for consultation in relation to the Code’s disclosure requirements on +44 (0)20 7638 0129.

The Code can be viewed on the Panel’s website at www.thetakeoverpanel.org.uk.

To Nasdaq Copenhagen A/S                        1 October 2026
                                        Announcement no. 84/2026
                                        Inside information

Cash Flows

Pursuant to S. 24 of the Capital Markets Act, we hereby publish cash flow data on bonds issued by Jyske Realkredit. Please find the data in the attached file.

The information will also be available on Jyske Realkredit’s web site at jyskerealkredit.com.

For further information about format of data and content of the file we refer to the web site of Nasdaq at www.nasdaqomxnordic.com.

Questions may be addressed to Christian Bech-Ravn, Head of Investor Relations, tel. (+45) 89 89 92 25.

Yours sincerely

Jyske Realkredit

Please observe that the Danish version of this announcement prevails

www.jyskerealkredit.com

Attachment

SATO Corporation, Press release, 1 October 2026 at 12:00 pm

The Act on Residential Leases (AHVL) has been amended today, 1 October. Originally adopted in 1995, the amended legislation introduced changes to areas including the smoking ban, grounds for terminating a lease agreement and notice periods.

The change that has attracted the most attention in advance in terms of tenants’ everyday lives is the smoking ban. From today onwards, the ban applies to indoor areas as well as to balconies and private yards belonging to the apartment. The change also applies to lease agreements concluded before the amended legislation entered into force.

“Cigarette smoke does not stop at the boundaries of an apartment but also affects neighbours. The smoking ban aims to improve living comfort and reduce the health risks caused by cigarette smoke. At SATO, we intend to follow the principles and spirit of the Residential Leases Act, even though the law also allows landlords to make exceptions. Treating our residents equally is important to us, which is why we will not grant individual exemptions from the smoking ban,” says Olli Tång, Executive Vice President responsible for SATO’s housing business.

Landlord’s notice period changed

Landlords’ notice periods for new lease agreements has also been changed. If the tenancy has lasted for at least two years, the landlord’s notice period is four months instead of the previous six. For shorter tenancies, the notice period remains unchanged at three months. When the tenant terminates the lease agreement, the notice period continues to be one month.

As a rule, new lease agreements are initially concluded for a fixed term of 12 months, after which they will continue until further notice.

“The reform aims to strike a better balance between tenants’ and landlords’ rights regarding notice periods, which is why the landlord’s notice period has been shortened somewhat for longer tenancies. In practical terms, very little changes with 12-month fixed-term agreements, as residents don’t need to sign a new agreement or separately notify us that they wish to continue living in their home once the fixed term ends. The agreement will continue automatically,” Tång points out.

Changes help address disturbances

From today onwards, landlords will have better means to address disturbances than before. Other exceptionally serious reasons can now also constitute grounds for terminating a lease agreement.

“Social and financial difficulties have increased significantly in our society, and in the rental housing business this is reflected in payment problems and an increase in disruptive behaviour. The change in legislation gives us as landlords an important tool for dealing with challenging situations and helps safeguard neighbours’ right to peaceful, disturbance-free everyday life. Maintaining an open and confidential dialogue with tenants also makes it easier to address disturbances.”

Under the new legislation, landlords have the right to enter an apartment at a time notified to the resident in advance, even if the time of the visit cannot be agreed with the resident

“Naturally, we will continue to make every effort to visit our residents’ homes at a time that suits them. We will also notify residents of an upcoming visit well in advance, unless the situation involves safety or another exceptional circumstance requiring an urgent response.”

Read more about the changes to the Residential Leases Act and how they affect living in a SATOhome: https://www.sato.fi/en/faq-rental-apartments#ahvl

For more information, please contact:
Olli Tång, EVP, Housing Business, tel. +358 20 134 4071, olli.tang@sato.fi

Media contact:
Terhi Jokinen, Senior Communications Specialist, tel. +358 20 134 4307, terhi.jokinen@sato.fi

SATO Corporation is an expert in sustainable rental housing and one of Finland’s largest rental housing providers. SATO owns around 27,500 rental homes in the Helsinki Metropolitan Area, Tampere and Turku.

SATO aims to provide excellent customer experience and a comprehensive range of urban rental housing alternatives with good access to public transport and services. We promote sustainable development and work in open interaction with our stakeholders.

SATO invests profitably, sustainably and with a long-term view. We increase the value of our assets through investments, divestments and repairs. In 2025, SATO celebrated its 85th anniversary. www.sato.fi/en

Sanoma Learning, Press Release, 1 October 2026 at 12:00 p.m. EET

Sanoma Learning launches Sanna, an AI teacher assistant designed to reduce teachers’ workload

Co-created with more than 1,500 teachers across Europe, Sanna addresses the need for educational AI tools that reduce teachers’ workload and support increasingly diverse needs in European classrooms. Built on trusted local learning materials and national curricula, Sanna provides safe and pedagogically grounded AI support for teachers.

Sanoma Learning today launched Sanna, an AI assistant designed specifically for teachers. Sanna helps teachers prepare lessons, create additional teaching materials, provide feedback, tailor learning activities to different student needs, and save time on routine tasks. The service will be available for free trial in the Netherlands, Spain, Italy, Poland, Belgium, Finland and Sweden.

Unlike general-purpose AI tools, Sanna has been developed specifically for education, aligned with national curricula and built on Sanoma Learning’s trusted educational content and responsible AI approach. Through initial testing in 2025 and a two-month pilot programme in 2026 involving more than 1,500 teachers across Europe, the solution was further developed through direct teacher feedback, studies, and interviews to ensure it meets the needs of real classrooms.

The demand for educational AI is rising

As schools increasingly explore the use of artificial intelligence, teachers are looking for AI solutions designed for education rather than consumer use. In Sanoma Learning’s 2026 European Teacher Survey (ETS), with over 20,000 teachers responding, between 75% and 93% of teachers said AI tools used in education should be developed for educational purposes rather than adapted from general-purpose AI applications. The findings are consistent with OECD research showing that generative AI can support learning when used within clear educational frameworks and guided by sound teaching practices.

“Sanna is co-created with schools and teachers to address some of the sector’s biggest challenges. As teachers face increasing pressure to meet diverse student needs while managing growing workloads, Sanna helps save time and create personalised learning materials more efficiently, so teachers can spend more time on what matters most: supporting their students”, explains Oleg Sokolov, Senior Director of Data & AI at Sanoma Learning.

Sanna builds on Sanoma Learning’s long-standing experience in developing educational content through its local publishers and digital learning solutions for schools across Europe. By combining advances in generative AI with trusted learning materials and teaching expertise, the company aims to provide practical support that reflects the realities of today’s classrooms.

“Many teachers are already using general AI tools, while our European Teacher Survey shows that most teachers are not convinced that general-purpose AI improves pupils’ learning outcomes. They want solutions they can trust in a school setting, and that is what we are now delivering,” said Sokolov.

How Sanna works

Sanna supports teachers with everyday classroom tasks, including lesson planning, creating assignments and assessments, adapting materials for different learning levels, developing additional classroom activities, providing feedback on student assignments, and creating presentations. Teachers can use Sanna in two ways:

  • Guided tools that help create differentiated lesson materials and other teaching resources for specific educational needs.
  • An AI chat interface where teachers can ask questions, explore ideas, refine content, and generate new materials.

Teachers remain in control over teaching decisions throughout the whole process. All AI-generated content can be reviewed, edited, adapted, and approved before it is used in the classroom. Designed specifically for schools, Sanna has been developed in line with Sanoma Learning’s principles for responsible AI and educational approach.

Sanna offers a safe pedagogical environment designed to comply with EU privacy and AI regulations. Sanoma’s Responsible AI approach is based on a set of core principles that provide a coherent foundation across pedagogical, didactic, legal and ethical dimensions. For example, our educational guardrails are designed to keep AI-generated outputs relevant for learning, our product UX is designed to ensure teachers remain in control and help limit over-reliance on AI, and all data is processed within Europe.

Sanna will be available for a 30-day trial from 1 October 2026 in selected European markets. Information about availability, subscription options, and pricing can be found at www.sanna.eu.

About Sanoma Learning

Sanoma Learning is Europe’s leading K12 learning company, serving about 25 million students across our markets. We support teachers and students with best-in-class learning content and solutions to help all students reach their potential.

Our blended offering combines printed and digital learning materials, digital platforms, and AI-driven solutions purpose-built for learning and teaching. We develop our learning materials and solutions in close collaboration with teachers and students to truly understand their needs and aspirations.

By combining deep pedagogical expertise with high-quality content, innovative technology and responsible use of AI, we create positive impact and help shape the future of K12 education.

Sanoma Learning is part of Sanoma, an innovative and agile learning and media company. Through learning and media, we have a positive impact on the lives of millions of people every day.

For more information about Sanoma Learning, visit our website: sanomalearning.com.

Resources

OECD (2026), OECD Digital Education Outlook 2026: Exploring Effective Uses of Generative AI in Education, OECD Publishing, Paris, https://doi.org/10.1787/062a7394-en.

Sanoma Learning (2026), 2026 European Teacher Survey: Education in evolution: Teachers are ready for AI but only when it is built for learning. Sanoma, Helsinki, Finland. https://www.sanomalearning.com/en/our-solutions/european-teacher-survey/

Sanna: www.sanna.eu

Contact information:

Johnny Anderson

Communication Director, Sanoma Learning
+47 932 40 192
Johnny.anderson@sanoma.com
communications@sanomalearning.com

Privacy Overview

This website uses cookies so that we can provide you with the best user experience possible. Cookie information is stored in your browser and performs functions such as recognising you when you return to our website and helping our team to understand which sections of the website you find most interesting and useful.